UPDATE: Wunderlich Securities Raises PT to $29 on Abiomed; Impella Exceeds Expectations

Wunderlich Securities raises its price target on Abiomed ABMD from $27 to $29 while reiterating its Buy rating on shares. Wunderlich Securities comments, "Abiomed (ABMD) reported outstanding Q4 results, as strong Impella revenue growth exceeded even our most optimistic scenario. Impella revenues increased a whopping 43%, accelerating significantly over the very strong growth witnessed in recent quarters and coming in far above our 30% expectation. We view the results as powerful confirmation of our thesis and our belief that Impella continues to gain rapidly increasing acceptance in the clinical community. All in all, this was the most impressive quarter to date for ABMD and Impella, as the story continues to get better and better." ABMD closed at $23.22 on Wednesday.